The trading price of Gilead Sciences, Inc (NASDAQ:GILD) floating higher at last check on current market day and closing at $115.51, 0.68% higher than its previous close.
The company’s P/E ratio in the trailing 12-month period was 314.67. In examining the 52-week price action we see that the stock hit a 52-week high of $117.39 and a 52-week low of $62.07. Over the past month, the stock has gained 17.42% in value.
Gilead Sciences, Inc, whose market valuation is $143.86 billion at the time of this writing, is expected to release its quarterly earnings report in April. The dividend yield on the company stock is 2.67%, while its Forward Dividend ratio is 3.08. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest GILD has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned GILD a recommendation rating is 17. Out of them, 6 rate it a Hold, while 11 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Gilead Sciences, Inc (GILD) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 12.76, which symbolizes a positive outlook. A quick review shows that GILD’s price is currently 8.10% off the SMA20 and 17.17% off the SMA50. The RSI metric on the 14-day chart is currently showing 76.09, and weekly volatility stands at 2.58%. When measured over the past 30 days, the indicator reaches 2.33%. Gilead Sciences, Inc (NASDAQ:GILD)’s beta value is currently sitting at 0.34, while the Average True Range indicator is currently displaying 2.60. With analysts defining $71-$105 as the low and high price targets, we arrive at a consensus price target of $94 for the trailing 12-month period. The current price is about 38.53% off the estimated low and 9.1% off the forecast high, based on this estimate. Investors will be thrilled if GILD’s share price rises to $94, which is the median consensus price. At that level, GILD’s share price would be 18.62% above current price.
To see how Gilead Sciences, Inc stock has been performing today in comparison to its peers in the industry, here are the numbers: GILD stock’s performance was 0.68% at last check in today’s session, and 59.75% in the past year. Gilead Sciences, Inc has a P/E ratio of 314.67, compared to Johnson & Johnson’s 28.38 and Pfizer Inc.’s 18.45.
An evaluation of the daily trading volume of Gilead Sciences, Inc (NASDAQ:GILD) indicates that the 3-month average is 7.49 million.
Currently, records show that 1.25 billion of the company’s shares remain outstanding. The insiders hold 0.19% of outstanding shares, whereas institutions hold 86.65%. However, since the stock’s price has seen 25.06% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
